Concord Drugs Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Seelam Reddy

Algemeen directeur

₹6.0m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	3.3yrs
Eigendom CEO	28.6%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Seelam Reddy's beloning veranderd ten opzichte van Concord Drugs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹92k
Mar 31 2024	₹6m	₹6m	₹5m
Dec 31 2023	n/a	n/a	₹10m
Sep 30 2023	n/a	n/a	₹17m
Jun 30 2023	n/a	n/a	₹13m
Mar 31 2023	₹6m	₹6m	₹10m
Dec 31 2022	n/a	n/a	₹9m
Sep 30 2022	n/a	n/a	₹8m
Jun 30 2022	n/a	n/a	₹11m
Mar 31 2022	₹4m	₹4m	₹16m
Dec 31 2021	n/a	n/a	₹19m
Sep 30 2021	n/a	n/a	₹42m
Jun 30 2021	n/a	n/a	₹38m
Mar 31 2021	₹2m	₹2m	₹33m
Dec 31 2020	n/a	n/a	₹30m
Sep 30 2020	n/a	n/a	₹4m
Jun 30 2020	n/a	n/a	₹4m
Mar 31 2020	₹1m	₹1m	₹3m
Dec 31 2019	n/a	n/a	₹4m
Sep 30 2019	n/a	n/a	₹4m
Jun 30 2019	n/a	n/a	₹4m
Mar 31 2019	₹2m	₹2m	₹4m

Compensatie versus markt: De totale vergoeding ($USD 71.12K ) Seelam } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.67K ).

Compensatie versus inkomsten: De vergoeding van Seelam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Seelam Reddy (55 yo)

3.3yrs

Tenure

₹6,000,000

Compensatie

Mr. Seelam Nagi Reddy served as Managing Director at Concord Drugs Limited until July 16, 2016 and served as its Compliance Officer. Mr. Reddy has been the Chairman and Whole-time Director of Concord Drugs...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Seelam Reddy	Chairman of the Board & MD	21.6yrs	₹6.00m	28.61% ₹ 107.4m
Seelam Reddy	CFO & Whole-Time Director	13.4yrs	₹2.40m	9.51% ₹ 35.7m
Seelam Manoj Reddy	Whole-Time Director	3.3yrs	₹2.40m	16.28% ₹ 61.1m
Kommula Reddy	Non-Executive Independent Director	5.7yrs	geen gegevens	0.50% ₹ 1.9m
Nagavenkata Hareesh Solleti	Non-Executive Independent Director	3.8yrs	geen gegevens	0.000010% ₹ 37.5
Sumeela Kasu	Independent Director	2.4yrs	geen gegevens	geen gegevens

4.7yrs

Gemiddelde duur

35yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 538965 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Concord Drugs Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Concord Drugs Limited, Annual General Meeting, Sep 30, 2024

Concord Drugs Limited, Annual General Meeting, Sep 30, 2024

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023

Less than half of directors are independent

Recent updates

Concord Drugs Limited, Annual General Meeting, Sep 30, 2024

Concord Drugs Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.03 (vs ₹0.53 in 1Q 2024)

Concord Drugs Limited to Report Q1, 2025 Results on Aug 09, 2024

New minor risk - Profit margin trend

New minor risk - Revenue size

Third quarter 2024 earnings released: ₹0.24 loss per share (vs ₹0.52 profit in 3Q 2023)

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹0.60 (vs ₹0.21 in 2Q 2023)

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 23%

Concord Drugs Limited to Report Q1, 2024 Results on Aug 14, 2023

Concord Drugs Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹1.06 (vs ₹1.82 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.52 (vs ₹0.48 in 3Q 2022)

Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023

Less than half of directors are independent

Concord Drugs Limited announced that it has received INR 10.364063 million in funding

Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Concord Drugs Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Concord Drugs Limited to Report Q1, 2023 Results on Aug 06, 2022

Investor sentiment improved over the past week

Concord Drugs Limited Announces Director Changes

Concord Drugs Limited to Report Q4, 2022 Results on May 30, 2022

Concord Drugs Limited Announces Resignation of Jyoti Goyal as Company Secretary and Compliance Officer

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.52 (vs ₹0.092 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

First quarter 2022 earnings released: EPS ₹0.79 (vs ₹0.19 in 1Q 2021)

Non-Executive Independent Director Pathakota Reddy has left the company

Full year 2021 earnings released: EPS ₹3.75 (vs ₹0.38 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹25.25

Third quarter 2021 earnings released: EPS ₹3.09 (vs ₹0.05 in 3Q 2020)

Concord Drugs Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day low: ₹21.75

Concord Drugs Limited, Annual General Meeting, Dec 29, 2020

Market pulls back on stock over the past week

New 90-day high: ₹19.35

First quarter earnings released

New 90-day high - ₹17.47

New 90-day low - ₹13.30

New 90-day low - ₹14.25

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd